NewsSource: EClinCloud

[Invitation] EClinCloud Invites You to the National Pharmaceutical Project Translation Forum

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration


On March 23–24, 2023, the National Pharmaceutical Project Translation Forum will be held at Chengdu Yujiang Hotel. The conference will showcase more than 50 high-potential, tradable pharmaceutical projects across areas including traditional Chinese medicine, chemical drugs, biologics, and medical devices, and will invite top 20 domestic pharmaceutical R&D service companies as well as R&D service enterprises with mature projects open to external collaboration to discuss topics including Marketing Authorization Holder (MAH) transfer, project initiation, and equity investment.


During the afternoon sub-forum on March 24, Dr. Qin Long, CEO of EClinCloud, has been invited to attend and will deliver a keynote presentation from 14:50–15:15 titled "Scale and Rating Management in Clinical Research." Starting from the concept of COA, he will detail the significance and value of scale management and rater training, and share the perspectives of global regulatory authorities on the use of eCOA. We look forward to exchanging insights and discussing with industry experts at the event!



Sub-forum: Drug R&D and Clinical Research

Presentation Time: Friday, March 24, 14:50–15:15

Presentation Topic: Scale and Rating Management in Clinical Research


Article illustration
Dr. Qin Long
CEO, EClinCloud


  • Over 17 years of experience in technology applications for the clinical research industry;

  • An innovative and inspiring leader, and a pioneer in promoting and implementing technology solutions such as eCOA, EDC, and CTMS in China's clinical trial research sector;

  • Previously served as Asia-Pacific head for multiple international technology companies, leading rapid regional business growth;

  • An entrepreneur driven by academics and science, dedicated with strong passion to shaping new models for the future of clinical trials.


Article illustration


*Note: To register for the conference and obtain more information, please follow the "Yaoyou Zhijia" (药友之家) WeChat official account.




About EClinCloud

EClinCloud is a technology company focused on clinical R&D, providing an integrated, interoperable all-in-one clinical trial cloud platform (including technology products such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent, as well as solutions such as scale management, linguistic validation, rater training, and data quality analysis) along with clinical trial endpoint assessment technologies across therapeutic areas (including oncology, central nervous system, and ophthalmology). By combining cutting-edge technology with life data, EClinCloud builds a globally leading, patient-centric clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration

Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.